Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C1LH
|
||||
| Former ID |
DIB010630
|
||||
| Drug Name |
DS-8273
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
| Company |
Daiichi sankyo
|
||||
| Target and Pathway | |||||
| Target(s) | D(1B) dopamine receptor | Target Info | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Dopaminergic synapse | |||||
| PANTHER Pathway | Dopamine receptor mediated signaling pathway | ||||
| Reactome | Dopamine receptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02076451) Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Daiichi Sankyo. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.